Imugene (ASX:IMU) secured an orphan drug designation from the US Food and Drug Administration for Vaxinia, a treatment candidate for bile tract cancer, according to a Wednesday filing with the Australian bourse.
The orphan drug designation will allow the drugmaker to receive tax credits, waiver of specific administration fees, and a seven-year market exclusivity for Vaxinia, the filing said.
Imugene's shares rose 4% in recent Tuesday trade.
Price (AUD): $0.05, Change: $+0.0020, Percent Change: +4.17%
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.